Quoin Pharmaceuticals Ltd DRC
$ 8.50
-2.75%
25 Feb - close price
- Market Cap 14,125,400 USD
- Current Price $ 8.50
- High / Low $ 9.04 / 8.21
- Stock P/E N/A
- Book Value -2.06
- EPS -29.17
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.99 %
- ROE -6.51 %
- 52 Week High 23.50
- 52 Week Low 5.01
About
Quoin Pharmaceuticals Ltd is a biotechnology company specializing in the development of innovative therapeutics aimed at rare diseases and unmet medical needs. Leveraging its expertise in drug delivery technologies, Quoin enhances the efficacy and safety profiles of established compounds, positioning itself as a key player in the specialty pharmaceuticals landscape. The company's promising pipeline includes therapies targeting critical conditions, presenting substantial opportunities for clinical advancement and market penetration. As Quoin advances through its clinical trials, it is committed to creating value for patients and shareholders through strategic partnerships and dedicated research initiatives.
Analyst Target Price
$40.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-11 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-08 | 2023-08-02 | 2023-05-08 | 2023-03-08 |
| Reported EPS | -6.72 | -6.3 | -6.502 | -0.2781 | -0.47 | -0.39 | -1.11 | -2.08 | -1.95 | -2.13 | -0.34 | -0.41 |
| Estimated EPS | -0.6 | -0.56 | -4.2 | -0.43 | -0.49 | -0.61 | -0.76 | -2.31 | -2.72 | -2.82 | -0.28 | -0.62 |
| Surprise | -6.12 | -5.74 | -2.302 | 0.1519 | 0.02 | 0.22 | -0.35 | 0.23 | 0.77 | 0.69 | -0.06 | 0.21 |
| Surprise Percentage | -1020% | -1025% | -54.8095% | 35.3256% | 4.0816% | 36.0656% | -46.0526% | 9.9567% | 28.3088% | 24.4681% | -21.4286% | 33.871% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -6.42 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QNRX
2026-02-17 20:57:15
Quoin Pharmaceuticals (QNRX) stock surged by 13.10% and crossed above its 20-day SMA, indicating strong investor interest. This rise occurs while the Nasdaq-100 is down, suggesting investors are shifting towards biotech companies with innovative approaches. The price movement is expected to draw more attention to Quoin's future developments as it focuses on therapies for rare and orphan diseases.
2026-02-16 16:48:42
Quoin Pharmaceuticals (QNRX) stock surged by approximately 157% after announcing a $104.5 million funding deal, which includes an initial cash infusion to support the clinical development of its lead candidate, QRX003, for Netherton Syndrome. This significant financial backing, combined with regulatory designations like Orphan Drug status and a Breakthrough Medicine Designation application for QRX003, suggests strong investor confidence in the company's rare disease pipeline and its potential market impact. The company is actively progressing with clinical trials and has a distribution partnership for market entry in the MENA region, further enhancing its prospects.
2026-02-16 15:36:15
Quoin Pharmaceuticals reported a GAAP EPS loss of $6.28 for Q2 2025, which surpassed analyst expectations despite R&D expenses tripling to $2.05 million. The company is making significant clinical progress with its lead asset QRX003 for Netherton Syndrome, including filing for Breakthrough Medicine Designation and receiving Orphan Drug status from the FDA and EMA.
2026-02-16 11:51:02
Quoin Pharmaceuticals' NETHERTON NOW awareness campaign has garnered over one million video views and 14 million impressions, significantly raising global awareness for Netherton Syndrome, a rare genetic skin disease. This campaign provides a platform for patients, families, and experts to share their experiences, aiming to improve understanding within both the medical community and the general public. Concurrently, Quoin's investigational drug, QRX003, is in late-stage clinical trials as the company strives to deliver the first approved treatment for this condition.
2026-01-31 07:27:26
An insider at Quoin Pharmaceuticals (NASDAQ:QNRX), Independent Director Dennis Langer, made a significant purchase of shares worth US$129k at US$8.49 each over the last year, indicating optimism even when the price was higher than the current US$8.30. Insider ownership stands at 6.8% (US$521k), which is considered moderate. While there haven't been recent insider transactions, the past year's buying activity is viewed positively by Simply Wall St.
2026-01-30 11:00:54
An independent director at Quoin Pharmaceuticals, Dennis Langer, significantly increased their shareholding by purchasing US$129k worth of shares at US$8.49 each over the past year. This insider buying, despite the stock now trading slightly lower at US$8.30, indicates optimism from within the company. Overall, insiders were net buyers, and hold 6.8% of the company, suggesting a degree of alignment with shareholder interests.
